Stopping Tumor Necrosis Factor-Alpha Inhibitors in Rheumatoid Arthritis (STARA)

https://www.niams.nih.gov/node/14351

Researchers want to see if people with RA in remission on a TNF inhibitor can stay in remission without this medicine. Also there may be a clinical, imaging (MRI, ultrasound), laboratory profile that will help to determine which patients remain in remission after stopping these drugs. This study will provide important new information on the best treatment approach for patients with RA in remission.

The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus

https://www.niams.nih.gov/node/14316

This is a double blind placebo-controlled study to characterize whether blocking type I IFN receptor signaling with anifrolumab will lead to improvements in vascular function, decreases in vascular inflammation and modulation of biomarkers of vascular risk in patients with systemic lupus erythematosus (SLE).

Subscribe to